Change of distribution partner in Portugal

September 19 | 2022

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today that it has changed its commercial partner in Portugal. Werfen, an IVD Global leader already distributing IndiTreat® in Spain, takes over the activities in the Portuguese market from Lab52. With this expanded partnership agreement, Werfen will leverage the synergies between their two companies, Werfen España and Werfen Portugal.

2cureX today announced today the extension of the IndiTreat® distribution agreement with Werfen. Under the terms of this extension, Werfen’s distribution territory now includes Spain, Portugal and Andorra. The agreement with the previous distributor, Lab52, has been terminated.

With a population of more than 10 million people and 10,500 new colorectal cancer patients every year, Portugal is a very important market for 2cureX. Its public healthcare system (Serviço Nacional de Saúde, SNS) is organized in eight health regions and has approximately 40 hospitals.

Strengthening the relationship with Werfen

“We are very excited to now also have Werfen as our partner in Portugal and that we have further strengthened our relationship,” says Fernando Andreu, CEO of 2cureX. “Werfen is a global leader in diagnostics, and because of their origin and history they are in an excellent position to leverage the synergies between two very close countries like Spain and Portugal.”

The best distributor for Portugal

“This is fantastic news,” says Jesper Floyd Kristiansen, VP Business Development at 2cureX. “Over the last twelve months, the Werfen team has demonstrated its strong commitment and dedication to IndiTreat® in Spain. We now have the best distributor in Portugal to bring the benefits of IndiTreat® to the Portuguese patients and healthcare professionals.”

The agreement with Werfen was signed in September 2021 for an initial term of three years. Other terms of the agreement have not been disclosed. Sales impact of this extension is expected to show in 2023.

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

About Werfen

Werfen (www.werfen.com), founded in 1966, is a worldwide developer, manufacturer and distributor of specialized diagnostic instruments, related reagents, automation workcells, and data management solutions for use primarily in hospitals and independent clinical laboratories. The Company’s business lines include Hemostasis, Acute Care Diagnostics (ACD), Autoimmunity, and Original Equipment Manufacturing (OEM). Werfen’s Hemostasis portfolio includes ACL TOP® Family 50 Series and ACL TOP Family Hemostasis Testing Systems, ACL AcuStar® system, ACL Elite® systems, HemoCell™ Specialized Lab Automation, HemoHub™ Intelligent Data Manager, along with the comprehensive line of HemosIL® assays. The ACD portfolio includes the GEM® Premier™ 5000 system with Intelligent Quality Management 2 (iQM®2), GEM Premier 3500 system with iQM, GEM Premier ChemSTAT™ system, GEMweb® Plus Custom Connectivity, ROTEM® viscoelastic testing systems, Hemochron™ systems, VerifyNow™ platelet function testing system, and Avoximeter™ CO-Oximeters. The Autoimmunity portfolio includes Aptiva®, BIO-FLASH®, NOVA View®, AUTOLoader and QUANTA-Lyser® 3000 systems, and QUANTA Link® data management solutions.

The OEM business line offers services for end-to-end development and manufacturing of customized immunoassays and biomaterials for diagnostic companies.

The Werfen logo is a trademark of Werfen. GEM, Premier, GEM Premier ChemSTAT, GEMweb, iQM, ChemSTAT, HemosIL, ACL, ACL TOP, ACL Elite, ACL AcuStar, ReadiPlasTin, RecombiPlasTin, SynthASil, SynthAFax, ROTEM, Hemochron, VerifyNow and Avoximeter are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies, and may be registered in the United States Patent and Trademark Office and in other jurisdictions. Aptiva, QUANTA-Lyser, QUANTA Lite, QUANTA Link, QUANTA Flash, NOVA View, NOVA Lite are registered trademarks of Inova Diagnostics, Inc. BIO-FLASH is a registered trademark of Biokit S.A. All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.